KS

Kaushal Shah

Active Director Director DIN 08384379
DIN 08384379 First appointment Mar 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2019
Shareholding value •••• Premium profile

About Kaushal Shah

Data last updated:

Kaushal Shah is a Director at Merganzer Pharma Private Limited (since 2019). The company operates in Pharma. Merganzer Pharma Private Limited reported revenue of ₹4.31 Cr (FY 2022).

DIN 08384379
Primary Designation Director
Industry Pharma
First Appointment 08 Mar 2019
Oldest Company Age 7 yrs
Largest company Merganzer Pharma Private Limited · ₹4.31 Cr (FY 2022)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Merganzer Pharma Private Limited U74999GJ2019PTC106991
Director08 Mar 20192019₹4.31 Cr (FY 2022)Active

Board colleagues of Kaushal Shah

Directorship timeline

Open interactive timeline →
Merganzer Pharma Private Limited
Premium access

Shareholding and investment profile for Kaushal Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kaushal Shah

Kaushal Shah currently holds 1 directorship: Merganzer Pharma Private Limited (Director, since 08 Mar 2019, revenue ₹4.31 Cr (FY 2022)).

Kaushal Shah was first appointed on 08 Mar 2019 as Director at Merganzer Pharma Private Limited.

The current boards of Kaushal Shah's companies include Kanan Kaushalbhai Shah (Merganzer Pharma Private Limited), Sanjay Shah (Merganzer Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available